5-Amino-1MQ Fat Loss Guide — Mechanism & Results 2026

Research published in Nature in 2019 demonstrated that NNMT (nicotinamide N-methyltransferase) inhibition via 5-Amino-1MQ produced 7% body weight reduction and significant visceral fat loss in diet-induced obese mouse models. Without corresponding muscle tissue loss. The mechanism isn't appetite suppression or hormonal manipulation. It's metabolic reprogramming at the cellular energy allocation level. Blocking NNMT increases intracellular NAD+ availability, which directly activates pathways that shift energy metabolism from glucose storage toward fat oxidation.

We've seen growing interest in 5-Amino-1MQ from researchers investigating non-stimulant metabolic interventions. Compounds that alter how cells allocate fuel rather than reducing caloric intake or raising thermogenesis. The gap between surface claims and actual mechanism matters here more than with most peptides.

What is 5-Amino-1MQ and how does it work for fat loss?

5-Amino-1MQ is a small molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that methylates nicotinamide and reduces NAD+ availability inside cells. By blocking NNMT, 5-Amino-1MQ raises intracellular NAD+ levels, which activates sirtuins and AMPK. Pathways that shift metabolism from anabolic glucose storage toward catabolic fat oxidation. Preclinical trials showed 7–15% body fat reduction without muscle loss over 10–11 weeks.

Most fat loss compounds work through one of three pathways: appetite suppression (GLP-1 agonists), thermogenesis (stimulants like ephedrine or clenbuterol), or hormonal modulation (thyroid analogs). 5-Amino-1MQ operates through none of these. It targets energy substrate partitioning at the mitochondrial level. NNMT is overexpressed in adipose tissue during obesity, which depletes NAD+ and reduces the cell's capacity for beta-oxidation. Inhibit NNMT and you restore NAD+ availability, reactivating the pathways that burn fat for fuel. This article covers the NNMT-NAD+ axis, dosing protocols used in research, realistic fat loss expectations, and what preparation errors render the compound ineffective.

The NNMT-NAD+ Pathway and Why It Matters for Fat Loss

NNMT (nicotinamide N-methyltransferase) is an enzyme that catalyzes the methylation of nicotinamide into N1-methylnicotinamide. A reaction that consumes one molecule of S-adenosylmethionine (SAM) and prevents nicotinamide from being recycled back into NAD+ via the salvage pathway. NAD+ (nicotinamide adenine dinucleotide) is the coenzyme required for sirtuin activity and mitochondrial beta-oxidation. The biochemical processes that break down fatty acids into ATP. When NNMT activity is elevated, intracellular NAD+ levels drop, sirtuins are inhibited, and metabolism shifts toward glucose utilization and triglyceride storage.

Research from the Kraus lab at Duke University identified NNMT as significantly upregulated in visceral adipose tissue during diet-induced obesity. The more NNMT present, the lower the NAD+ concentration. And the lower the NAD+ concentration, the less fatty acid oxidation occurs. 5-Amino-1MQ works as a competitive inhibitor, binding to the NNMT active site and preventing the enzyme from methylating nicotinamide. This restores NAD+ availability and reactivates SIRT1 and AMPK, both of which promote mitochondrial biogenesis and shift substrate preference from carbohydrate to fat.

The critical insight: 5-Amino-1MQ doesn't create a caloric deficit or suppress hunger. It changes which fuel the cell preferentially burns when energy is required. In a 2019 Nature Communications study, mice treated with 5-Amino-1MQ showed 35% increased energy expenditure from fat oxidation compared to controls, despite identical caloric intake. The effect scaled with NNMT expression. Tissues with higher baseline NNMT (white adipose tissue, liver) responded more strongly than tissues with low NNMT (skeletal muscle).

Dosing Protocols and Administration in Research Settings

5-Amino-1MQ has been studied almost exclusively in preclinical animal models. No published Phase 1 human trials exist as of 2026. The most cited dosing protocol comes from the 2019 Nature Communications paper, which administered 5-Amino-1MQ at 50 mg/kg/day via subcutaneous injection in C57BL/6 mice for 10 weeks. Dose scaling from mouse to human using allometric conversion (dividing mouse dose by 12.3) suggests a human equivalent dose of approximately 4 mg/kg/day. Roughly 280–320 mg/day for a 70–80 kg individual.

Research-grade 5-Amino-1MQ is supplied as lyophilized powder and reconstituted with bacteriostatic water at concentrations ranging from 10–25 mg/mL. Subcutaneous administration is standard. Intramuscular or oral bioavailability has not been characterized. Storage requires refrigeration at 2–8°C post-reconstitution, with a maximum shelf life of 28 days once mixed. Temperature excursions above 8°C denature the compound irreversibly. A common failure point when peptides are stored incorrectly or shipped without cold chain protocols.

The dosing frequency in published protocols was daily subcutaneous injection. No loading phase or titration schedule was used. Mice received the full dose from day one. Plasma half-life data for 5-Amino-1MQ has not been published, so optimal injection timing (morning vs evening, fasted vs fed) remains unclear. Anecdotal reports from research communities suggest splitting the dose into twice-daily injections to maintain more stable plasma levels, but this has no empirical support.

Realistic Fat Loss Expectations and Timeline

The Nature Communications trial showed mice treated with 5-Amino-1MQ lost an average of 7% body weight over 10 weeks compared to controls, with fat mass reductions ranging from 20–30% in visceral adipose depots. Lean mass (skeletal muscle) was preserved. DEXA scans confirmed no significant difference in muscle mass between treatment and control groups. This is the central selling point: fat-specific reduction without muscle catabolism, which distinguishes NNMT inhibition from caloric restriction or GLP-1 agonists (both of which typically produce 25–30% lean mass loss alongside fat loss).

Extrapolating these results to humans requires caution. Mice are not metabolically identical to humans. Their baseline metabolic rate, NNMT expression patterns, and NAD+ salvage pathway efficiency differ significantly. A realistic conservative estimate: 5-Amino-1MQ might produce 5–10% body fat reduction over 12–16 weeks in humans with elevated NNMT expression (i.e., individuals with existing obesity or metabolic syndrome). Lean individuals with low baseline NNMT may see minimal effect.

The timeline matters. Fat oxidation via the NAD+-sirtuin-AMPK axis is gradual. This is not a rapid water-loss or glycogen-depletion mechanism. Meaningful changes in body composition become visible after 6–8 weeks, with maximal effect at 12–14 weeks. Stopping the compound does not trigger immediate rebound because the mechanism is not appetite suppression. But NAD+ levels will normalize within days of cessation, and metabolic partitioning will revert to baseline.

5-Amino-1MQ Fat Loss Complete Guide 2026: Comparison

Understanding how 5-Amino-1MQ compares to established fat loss interventions clarifies where it fits in metabolic research and why its mechanism is fundamentally different.

5-Amino-1MQ occupies a unique position: it's the only intervention on this list that works without reducing caloric intake, raising heart rate, or altering appetite signaling. The tradeoff is absence of human clinical data. Every number cited for 5-Amino-1MQ comes from mouse models.

Key Takeaways

• 5-Amino-1MQ inhibits NNMT, raising intracellular NAD+ levels and activating pathways (SIRT1, AMPK) that shift metabolism from glucose storage to fat oxidation.
• Preclinical trials in mice demonstrated 7% body weight reduction and 20–30% visceral fat loss over 10 weeks with preserved lean mass.
• The human equivalent dose derived from allometric scaling is approximately 280–320 mg/day via subcutaneous injection, though no Phase 1 human trials have been published.
• 5-Amino-1MQ requires refrigeration at 2–8°C post-reconstitution and loses potency irreversibly if exposed to temperatures above 8°C.
• The compound does not suppress appetite or increase thermogenesis. Fat loss occurs through metabolic substrate partitioning, not caloric deficit.
• Realistic expectations: 5–10% body fat reduction over 12–16 weeks in individuals with elevated baseline NNMT expression (obesity, metabolic syndrome).

What If: 5-Amino-1MQ Fat Loss Scenarios

What If I Store Reconstituted 5-Amino-1MQ at Room Temperature Overnight?

Discard the vial. Peptides denature irreversibly at ambient temperature. The molecular structure unfolds, the active site loses function, and no amount of re-cooling restores potency. A single 12-hour temperature excursion above 8°C renders the compound inactive, turning an effective NNMT inhibitor into a saline injection. Use a dedicated peptide refrigerator or a medication cooler with verified temperature logging if storing at home.

What If I Don't See Fat Loss After Six Weeks of Daily Injections?

Verify three things: proper reconstitution (bacteriostatic water, correct concentration), refrigerated storage without temperature excursions, and subcutaneous administration technique (not intramuscular, not intradermal). If all three are confirmed, the issue is likely low baseline NNMT expression. Individuals who are already lean or metabolically healthy may not have elevated NNMT to inhibit. 5-Amino-1MQ works by blocking an overactive enzyme; if the enzyme isn't overactive, blocking it produces minimal effect.

What If I Want to Combine 5-Amino-1MQ With a GLP-1 Agonist?

The mechanisms don't overlap. GLP-1 agonists suppress appetite and slow gastric emptying, while 5-Amino-1MQ increases fat oxidation without altering hunger signaling. No pharmacokinetic interaction has been studied, but combining them theoretically addresses fat loss through two independent pathways: caloric deficit (GLP-1) and metabolic partitioning (NNMT inhibition). Monitor for additive metabolic stress and consult with a research physician if planning concurrent use.

The Direct Truth About 5-Amino-1MQ and Fat Loss Claims

Here's the honest answer: 5-Amino-1MQ has zero published human clinical data as of 2026. Every fat loss claim you've read online extrapolates from a single preclinical mouse study published in 2019. The mechanism is sound. NNMT inhibition does raise NAD+ and activate fat oxidation pathways. But translating a 7% body weight reduction in C57BL/6 mice to humans is speculative at best.

The compound isn't FDA-approved. It's not in Phase 1 trials. It exists in a regulatory gray zone as a research chemical available from peptide suppliers like Real Peptides, where quality control depends entirely on third-party purity testing (HPLC, mass spectrometry). Some batches test at 98%+ purity. Others don't. You're trusting small-batch synthesis without the oversight that governs pharmaceutical manufacturing.

Does it work? Probably. If your NNMT is elevated, if your dose is correct, if your storage protocol prevents denaturation, and if you're patient enough to wait 12–16 weeks for meaningful fat oxidation. Will it outperform semaglutide or a structured caloric deficit? Almost certainly not. But if you're researching non-appetite-based metabolic interventions and want to explore NAD+ pathway modulation, 5-Amino-1MQ represents one of the most mechanistically interesting compounds available in 2026.

The Role of NAD+ Precursors and Synergistic Compounds

NNMT inhibition works by preventing NAD+ depletion. But NAD+ synthesis also depends on substrate availability. Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are NAD+ precursors that bypass the NNMT bottleneck entirely, entering cells and converting directly into NAD+ via the salvage pathway. Combining 5-Amino-1MQ with NR or NMN theoretically maximizes intracellular NAD+ concentration from both directions: blocking degradation (NNMT inhibition) and increasing synthesis (precursor supplementation).

Research from Sinclair's lab at Harvard demonstrated that NMN supplementation at 300–500 mg/day raised NAD+ levels by 40–60% in human skeletal muscle. When combined with exercise, the effect on mitochondrial biogenesis was additive. No published studies have tested 5-Amino-1MQ plus NMN in combination, but the biochemical logic is sound. If NAD+ availability is the limiting factor for fat oxidation, addressing it from multiple angles should amplify the effect.

Resveratrol, a SIRT1 activator, represents another potential synergy. SIRT1 requires NAD+ as a cofactor to deacetylate target proteins involved in mitochondrial function and fat metabolism. Raising NAD+ without activating sirtuins leaves half the pathway unstimulated. Resveratrol at 150–300 mg/day could theoretically enhance the downstream effect of elevated NAD+ induced by NNMT inhibition. Again, no empirical data exists, but mechanistic plausibility is high.

5-Amino-1MQ works because it removes a metabolic brake. NNMT overexpression. That prevents cells from accessing stored fat efficiently. The compound doesn't replace proper nutrition, resistance training, or sleep hygiene. It shifts substrate partitioning in a way that makes fat oxidation easier when energy demand is present. If you're sitting sedentary with excess caloric intake, raising NAD+ won't overcome thermodynamic reality. But if you're in a slight deficit or maintaining weight with structured activity, NNMT inhibition might tilt the balance toward preferential fat utilization.

For researchers exploring peptide-based metabolic interventions, our catalog includes compounds that address complementary pathways. Tesofensine for appetite modulation, MK 677 for growth hormone secretion, and NAD+ precursors that synergize with NNMT inhibition. Every batch undergoes third-party purity verification to ensure consistency in small-batch synthesis.